Royalty Pharma(US:RPRX) Globenewswire·2025-10-09 20:15Core Insights - Royalty Pharma plc will report its third quarter 2025 financial results on November 5, 2025, before U.S. financial markets open [1] - A conference call and webcast will be held at 8:00 a.m. Eastern Time on the same day [1] Company Overview - Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation in the biopharmaceutical industry [3] - The company collaborates with various entities, including academic institutions, research hospitals, non-profits, small and mid-cap biotechnology companies, and leading global pharmaceutical companies [3] - Royalty Pharma's portfolio includes royalties on over 35 commercial products and 17 development-stage product candidates [3] - Notable products in its portfolio include Vertex's Trikafta, Johnson & Johnson's Tremfya, GSK's Trelegy, and others [3]